Management of iron deficiency anemia with ferric carboxymaltose during pregnancy

There has been a dearth of scientific statistics aiding the efficacy and protection of ferric carboxymaltose (FCM) infusion in pregnant Indian girls 

This was converted to a subgroup analysis of the PROMISE trial, which was previously conducted in a real-world, multicentre,

Among the 1,191 protected pregnant women in the subgroup examined, IV FCM significantly increased hemoglobin (Hb)

serum ferritin to 30.03 μg/L at four weeks (P < 0.001 for both). Hb expanded to 3.6 g/dL (P<0.001) and serum ferritin with the help of sixteen.

serum ferritin to 30.03 μg/L at four weeks (P < 0.001 for both). Hb expanded to 3.6 g/dL (P<0.001) and serum ferritin with the help of sixteen.

Ninety-six μg/L (P = 0.12), all of which have been statistically of good size will increase in 103 pregnant women with excessive ADI

Significant increases in serum ferritin using 33 μg/L and Hb up to 2.74 g/dL (P<0.001 for each) were observed in 978 pregnant women with mild IDA.

mplicit corpuscular volume, mean corpuscular hemoglobin, hematocrit, and red cell dependency were greatly increased (P < zero.001 for all)

Need More Stories